Identification of the Major Molecular Types of Cryptococcus neoformans and C. gattii by Hyperbranched Rolling Circle Amplification

Luciana Trilles1,2, Bin Wang3, Carolina Firacative1, Márcia dos Santos Lazéra2, Bodo Wanke2, Wieland Meyer1

1 Molecular Mycology Research Laboratory, Centre for Infectious Diseases and Microbiology, Sydney Medical School – Westmead Hospital, Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Westmead Millennium Institute for Infectious Diseases and Biosecurity, Sydney, Australia, 2 Instituto de Pesquisa Clínica Evandro Chagas, FIOCRUZ, Laboratório de Micologia, Rio de Janeiro, Brazil, 3 Westmead Millennium Institute, University of Sydney, Retroviral Genetic Laboratory, Centre for Virus Research, Sydney, Australia

Abstract
The agents of cryptococcosis C. neoformans and C. gattii are important agents of meningoencephalitis in immunocompromised and immunocompetent hosts, respectively. They are grouped into eight major molecular types, VNI-VNIV for C. neoformans and VGI-VGIV for C. gattii. These major molecular types differ in their host range, epidemiology, antifungal susceptibility and geographic distribution. To enable a rapid identification of the major molecular types and potential hybrids within the two species specific probes based on the PLB1 gene in combination with hyperbranched rolling circle amplification (HRCA) were developed. HRCA was applied to 76 cryptococcal strains, 10 strains each representing the 7 haploid major molecular types, 4 VNIII hybrid strains and 2 inter-species hybrid strains. All strains were correctly identified to the major molecular type and or hybrid type using HRCA alone. To increase the sensitivity a semi-nested PCR step was developed, which will enable the identification of the molecular types/hybrids directly from clinical samples, harboring a low copy number of DNA (40 copies). Thus, HRCA based on the PLB1 locus alone and in combination with a semi-nested PCR showed to be a specific and sensitive methodology, with a great potential to be used on clinical specimens for the direct diagnosis of the agents of cryptococcosis, including hybrid strains, enabling a rapid and patient tailored treatment choice of this disease.

Introduction
Cryptococcosis is a systemic mycosis acquired by inhalation of infectious propagules (desiccated yeasts cells or spores) produced by the basidiomycetous yeasts Cryptococcus neoformans and C. gattii. Most clinical laboratories do not routinely identify the isolates to species level. However, cryptococcosis is associated with a significant morbidity and mortality and is the most common invasive fungal infection in HIV patients, with an estimated incidence of 1 million cases annually [1], mainly caused by C. neoformans. C. gattii on the other hand affects mostly immunocompetent individuals [2,3]. Molecular epidemiological studies have identified eight major molecular types within both species. The C. neoformans molecular types correlate with the serotypes: VNI/AFLP1, serotype A; VNI/AFLP1A, serotype A; VNIII/AFLP3, serotype AD; and VNIV/AFLP2, serotype D. The molecular types of C. gattii (VG1/AFLP4; VGII/AFLP6; VGIII/AFLP5; VGIV/AFLP7) are all associated with both serotypes B and C [4].

The major molecular types of C. neoformans and C. gattii differ in their epidemiological [5], ecological characteristics, antifungal susceptibility [6], clinical presentations and therapeutic outcomes [1]. Infections caused by C. gattii often have a worse prognosis than those caused by C. neoformans [7]. The determination of the molecular types becomes important as epidemics have occur in the recent years by the molecular type VGII in the southwest of Canada and VGIII in the northwest of the USA, indicating the ability of this species to adapt to new environments [4,8].

The currently used laboratory identification model for the agents of cryptococcosis has major limitations. Cryptococcus species are identified after culturing the isolates from a clinical sample followed by biochemical tests, which may delay the final diagnoses [9]. Furthermore, culture from a clinical sample is not always available, and direct examination can be imprecise, especially in the presence of atypical cells. In addition, the major molecular types within C. neoformans and C. gattii are then determined using a variety of molecular typing techniques [10,11,12,13], prolonging the time of the diagnostic process.

Molecular methods have the advantage of being highly sensitive and specific to overcome the limitations of conventional diagnosis [14,15]. Although molecular methods for the diagnosis of mycosis...
from clinical specimens and cultures are available, they are not yet applied in routine diagnosis laboratories [16].

In 2009, the ISHAM working group on “Genotyping C. neofor-
mans and C. gattii” developed a consensus MultiLocus Sequence Typing (MLST) scheme for the members of the C. neoformans/C. gattii species complex based on the variable regions within the capsular associated protein gene (CAP59), glyceraldehyde-3-phosphate dehydrogenase gene (GPD1), laccase (LAC1), phospholipase (PLB1), Cu, Zn superoxide dismutase (SOD1), orotidine monophosphate pyrophosphorylase (URA5) genes and intergenic spacer regions (IGS1), to standardize, increase the discriminatory power and improve the inter-laboratory reproducibility of cryptococcal genotyping [13]. The generated typing results, including allele and sequence types are searchable at http://mlst.mycologylab.org. In addition four VNIII hybrid isolates (VNI/VNIV) and 2 inter-species hybrid isolates VNI/VGII [24] were studied in the IGS1 region. They originated from 232 C. neofor-
mans/C. gattii strains including allele and sequence types are searchable at http://mlst.mycologylab.org. In addition four VNIII hybrid isolates (VNI/VNIV) and 2 inter-species hybrid isolates VNI/VGII [24]

DNA Extraction and MLST Typing

DNA extractions were performed according to Ferrer et al. [25]. The seven MLST loci, CAP59, GPD1, LAC1, SOD1, URA5, PLB1 and IGS, were amplified according to the consensus MLST scheme for C. neofor-
mans and C. gattii [13], except for the primers used to amplify the genes GPD1 and LAC1 of C. neofor-
mans. The GPD1 locus of C. neofor-
mans was amplified using the primers GPD1cn-F 5'- ATGGTCTGTCAGGTTTGAAT-3' and GPD1cn-R 5'- GTATTAGGCACACCTCAGC-3' and the LAC1 locus of C. neofor-
mans was amplified using the primers LAC1cn-F 5'- GGGTACACTATTTGCTGAAT-3' and LAC1cn-R 5'- TTCTGGAGTGGCGTGAACG-3' [26]. Allele (AT) and se-

Hyperbranched Rolling Circle Amplification (HRCA)

Amplification of the PLB gene. Amplification of the PLB gene was performed in a final volume of 50 μL. Each reaction contained 50 ng of DNA, 1X PCR buffer (200 mM Tris-HCl (pH 8.4), 500 mM KCl - Invitrogen), 0.2 mM each of dATP, dGTP, and dITP (Invitrogen), 2 mM magnesium chloride, 1.5 U Taq DNA polymerase (Invitrogen), and 50 ng of each primer PLB1-F (5’-CTTCAGGGCGAGAGGT3’) and PLB1-R (5’-GATTTGCGGTGATTTG3’) [14]. PCR was performed in a thermocycler (Perkin Elmer, California, USA) as follow: Initial denaturation at 94°C 3 min, followed by 30 cycles at 94°C 30 sec., annealing at 61°C 45 sec.; extension at 72°C 1 min; and final extension at 72°C 10 min at 94°C [13].

Semi-nested PCR. To enhance the sensitivity of the target DNA detection a semi-nested PCR strategy was developed. Nested-primers with 100% homology to the PLB1 gene of C. neofor-
mans and C. gattii were designed (Table 2) using sequences downloaded from GeneBank (Table S1). The conditions for the semi-nested PCR were the same as the ones used for the initial PLB1 gene amplification (see above), using 15 μL of the initial amplicon.

Padlock probe and primer design. Padlock probes were designed to target specific single nucleotide polymorphism (SNP) for each of the seven major haploid molecular types of the C. neofor-
mans (VNI, VNII, and VNIV) and C. gattii (VGI, VGII, VGIH, and VGV). The selection of informative SNPs was based on sequences maintained in the C. neofor-
mans/C. gattii MLST database from the Molecular Mycology Laboratory, Sydney University, Australia, http://mlst.mycologylab.org, and additional sequences generated as part of the current study. The sequences used for the SNP analysis included seven unlinked genetic loci: the housekeeping genes CAP59, GPD1, LAC1, PLB1, SOD1, URA5 and the IGS1 region. They originated from 232 C. neofor-
mans (201 VNI, 20 VNII, 11 VNIV) and 359 C. gattii (35 VGI, 184 VGII, 126 VGIII, 14 VGIV) global strains. To identify specific SNPs for each of the seven major haploid molecular types the sequences from the 591 C. neofor-
mans and C. gattii isolates were aligned using...
Table 1. Strains tested in this study and the results obtained by HRCA.

| Molecular Type by RFLP-URA5 and ISHAM MLST scheme | Strain       | Specific Probes |
|--------------------------------------------------|--------------|-----------------|
|                                                  | VNI          | VNI            | VNV   | VGA  | VGII | VGIII | VGIV |
| VNI                                              | WM 05.474    | +              | -     | -    | -    | -     | -    |
| VNI                                              | WM 05.524    | +              | -     | -    | -    | -     | -    |
| VNI                                              | WM 05.553    | +              | -     | -    | -    | -     | -    |
| VNI                                              | WM 05.557    | +              | -     | -    | -    | -     | -    |
| VNI                                              | WM 09.168    | +              | -     | -    | -    | -     | -    |
| VNI                                              | WM 148³      | +              | -     | -    | -    | -     | -    |
| VNI                                              | WM 1641      | +              | -     | -    | -    | -     | -    |
| VNI                                              | WM 1897      | +              | -     | -    | -    | -     | -    |
| VNI                                              | WM 419       | +              | -     | -    | -    | -     | -    |
| VNI                                              | WM 721       | +              | -     | -    | -    | -     | -    |
| VNI                                              | WM 05.483    |               | +     | -    | -    | -     | -    |
| VNI                                              | WM 05.484    |               | +     | -    | -    | -     | -    |
| VNI                                              | WM 05.485    |               | +     | -    | -    | -     | -    |
| VNI                                              | WM 05.486    |               | +     | -    | -    | -     | -    |
| VNI                                              | WM 05.490    |               | +     | -    | -    | -     | -    |
| VNI                                              | WM 05.491    |               | +     | -    | -    | -     | -    |
| VNI                                              | WM 1412      |               | +     | -    | -    | -     | -    |
| VNI                                              | WM 1462      |               | +     | -    | -    | -     | -    |
| VNI                                              | WM 553       |               | +     | -    | -    | -     | -    |
| VNI                                              | WM 626³      |               | +     | -    | -    | -     | -    |
| VNI                                              | WM 01.126    |               |       | +    | -    | -     | -    |
| VNI                                              | WM 02.142    |               |       | +    | -    | -     | -    |
| VNI                                              | WM 04.168    |               |       | +    | -    | -     | -    |
| VNI                                              | WM 04.171    |               |       | +    | -    | -     | -    |
| VNI                                              | WM 04.172    |               |       | +    | -    | -     | -    |
| VNI                                              | WM 04.174    |               |       | +    | -    | -     | -    |
| VNI                                              | WM 05.469    |               |       | +    | -    | -     | -    |
| VNI                                              | WM 1740      |               |       | +    | -    | -     | -    |
| VNI                                              | WM 2242      |               |       | +    | -    | -     | -    |
| VNI                                              | WM 629³      |               |       | +    | -    | -     | -    |
| VNI (VNI+VNI)                                    | WM 628³      | +              | -     | -    | -    | -     | -    |
| VNI (VNI+VNI)                                    | WM 329       | +              | -     | -    | -    | -     | -    |
| VNI (VNI+VNI)                                    | WM 1354      | +              | -     | -    | -    | -     | -    |
| VNI (VNI+VNI)                                    | WM 1738      | +              | -     | -    | -    | -     | -    |
| VNI+VGII                                         | WM 05.532    |               | +     | -    | -    | +     | -    |
| VNI+VGII                                         | WM 05.272    | +              | -     | -    | -    | +     | -    |
| VGA                                              | WM 02.103    |               |       | -    | +    | -     | -    |
| VGA                                              | WM 05.410    |               |       | -    | +    | -     | -    |
| VGA                                              | WM 1218      |               |       | -    | +    | -     | -    |
| VGA                                              | WM 179³      |               |       | -    | +    | -     | -    |
| VGA                                              | WM 1917      |               |       | -    | +    | -     | -    |
| VGA                                              | WM 200       |               |       | -    | +    | -     | -    |
| VGA                                              | WM 2571      |               |       | -    | +    | -     | -    |
| VGA                                              | WM 352       |               |       | -    | +    | -     | -    |
| VGA                                              | WM 727       |               |       | -    | +    | -     | -    |
| VGA                                              | WM 834       |               |       | -    | +    | -     | -    |
| VGII                                             | WM 05.77     |               |       | -    | +    | -     | -    |
| VGII                                             | WM 06.12     |               |       | -    | +    | -     | -    |
The specific sequence probes were designed with minimum secondary structure, as well as the 5'-end probe-binding arm Tm close to or above the ligation temperature (60°C, see below) to guarantee the effectiveness of padlock probe binding. The flanking linker region has no similarity to the respective major molecular type as defined via BlastN searches against the GenBank database. To increase 3'-end binding specificity, the 3'-end probe-binding arm was designed with Tm 10–15°C below the ligation temperature.

In addition, the primers RCA1 and RCA2 (Table 2), which are used to amplify the specific padlock probe signal during HRCA, were designed specifically to bind to the flanking linker regions of the above designed padlock probes with a Tm of about 55°C following the strategy described by Kaocharoen et al. [22].

**Padlock probe ligation, exonucleolysis and signal amplification by HRCA.** After amplification of the \( PLBI \) gene either by single or semi-nested PCR (see above), the amplicons were purified with the PureLink PCR purification kit (Invitrogen, USA). The ligation of the padlock probes to the amplified PCR products was performed according to Wang et al. [20], in a total reaction volume of 10 μl containing 75 ng of amplicon, 2 U of Pfu DNA ligase (Stratagene, Integrated Sciences) and 1 pmol of the padlock probe in 20 mM Tris-HCl (pH 7.5), 20 mM KCl, 10 mM MgCl₂, 0.1% Igepal, 0.01 mM ATP, 1 mM DTT. The ligation reaction conditions included 5 min denaturation at 94°C followed by 15 cycles of 94°C for 30 s and 4 min ligation at 65°C. The ligation mixture was then subjected to exonucleolysis to remove non-circularized padlock probe and excess PCR product in order to reduce subsequent ligation-independent amplification events. The exonuclease digestion was performed in a volume of 20 μl by adding 10 U of each exonucleases I and III (New England Biolabs) to the ligation solution and incubating it at 37°C for 5 min followed by 94°C for 30 s to inactivate the exonuclease.

HRCA reactions were performed in a volume of 50 μl by adding 8 U of *Bst* DNA polymerase (New England Biolabs), 400 μM deoxynucleoside triphosphate mix, 10 pmol of each RCA primers (Table 2), 5% of dimethyl sulfoxide (v/v), and 1× SYBR Green I (Sigma-Aldrich) to the digested mixture.

### Table 1. Cont.

| Molecular Type by RFLP-URAS and ISHAM MLST scheme | Strain | Specific Probes |
|--------------------------------------------------|--------|----------------|
|                                                  |        | VNI | VNII | VNI | VGII | VGIII | VGIV |
| VGI                                              | WM 11.128 | -   | -   | -   | +    | -     | -    |
| VGII                                             | WM 176 | -   | -   | -   | +    | -     | -    |
| VGII                                             | WM 3030 | -   | -   | -   | +    | -     | -    |
| VGII                                             | WM 1255 | -   | -   | -   | +    | -     | -    |
| VGII                                             | WM 02.32 | -   | -   | -   | +    | -     | -    |
| VGII                                             | WM 06.25 | -   | -   | -   | +    | -     | -    |
| VGII                                             | WM 05.272 | -   | -   | -   | +    | -     | -    |
| VGII                                             | WM 1008 | -   | -   | -   | +    | -     | -    |
| VGII                                             | WM 10.121 | -   | -   | -   | +    | -     | -    |
| VGII                                             | WM 10.17 | -   | -   | -   | +    | -     | -    |
| VGII                                             | WM 175 | -   | -   | -   | +    | -     | -    |
| VGII                                             | WM 2088 | -   | -   | -   | +    | -     | -    |
| VGII                                             | WM 728 | -   | -   | -   | +    | -     | -    |
| VGII*                                            | WM 11.133 | -   | -   | -   | +    | -     | -    |
| VGII*                                            | WM 1802 | -   | -   | -   | +    | -     | -    |
| VGII*                                            | WM 2004 | -   | -   | -   | +    | -     | -    |
| VGII*                                            | WM 2042 | -   | -   | -   | +    | -     | -    |
| VGII*                                            | WM 11.32 | -   | -   | -   | +    | -     | -    |
| VGIV                                             | WM 04.20 | -   | -   | -   | +    | -     | -    |
| VGIV                                             | WM 2363 | -   | -   | -   | +    | -     | -    |
| VGIV                                             | WM 779 | -   | -   | -   | +    | -     | -    |
| VGIV                                             | WM 780 | -   | -   | -   | +    | -     | -    |
| VGIV                                             | WM 05.376 | -   | -   | -   | +    | -     | -    |
| VGIV                                             | WM 08.314 | -   | -   | -   | +    | -     | -    |
| VGIV                                             | WM 1434 | -   | -   | -   | +    | -     | -    |
| VGIV                                             | WM 2567 | -   | -   | -   | +    | -     | -    |
| VGIV                                             | WM 2570 | -   | -   | -   | +    | -     | -    |
| VGIV                                             | WM 2604 | -   | -   | -   | +    | -     | -    |

**Note:** +: Positive signal with the specific probe; -: No signal with the specific probe;

*VGII* only when determined by the ISHAM MLST scheme, URAS RFLP is grouping them incorrectly to VGIV due to a point mutation in the RFLP restriction site; \(^{2}\): standard strain for the major molecular type (Meyer et al. 2009).

doi:10.1371/journal.pone.0094648.t001
Table 2. Padlock probes and padlock probe primers.

| Probes and primers | Sequence |
|--------------------|----------|
| VNI 5'-p-TCM CGA GCC TCA ATG TAG GCT CAT gct tct tgg gtc ccc at g GTT AGC TGG GCA TGC CAC Tgc cag aca gat CTA GCK CRA TTR CAG GTT GGA CAA GTT TC-3' |
| VNI 5'-p-TCA GTA GAT GAC CTA CAT CAT GCA CAT gct tct tgg gtc ccc at ACG ACTG CAG GAT AGC GTA Gcg cag aca gat CTA CCA GAG CTA TCA CCC A-3' |
| VNI 5'-p-GAT AAA TAA TGG GCA TAT CCT TGG CTA t gct tct tgg gtc ccc at CCT ACT AGT TGC AGC CTG TTC gcc gcg acg atg GTA TAA ACC CTG TAC TGC GGC AAC-3' |
| VGI 5'-p-GCA GCA TTA ACC CTA CAG GAT CAT gct tct tgg gtc ccc atT CTA GTA CAG AGC TTC TCC Gcc gcg acg aca tag TCT AGT CAA CAA TAA TAA TIA GGC ATA TCT TTC-3' |
| VGI 5'-p-ATA CCA CCC AAC CAA GTA CGA TCA t gct tct tgg gtc ccc atT CTA GTA CAG AGC TTC TCC Gcc gcg acg aca tag TCT AGT CAA CAA TGA CAG GTC TGC TTA-3' |
| VGII 5'-p-GGG AGG AGT TTC GAG CCC GAT CTA gct tct tgg gtc ccc atT CTA GTA CAG AGC TTC TCC Gcc gcg acg aca tag TCT AGT CAA CAA TGA CAG GTC TGC TTA-3' |
| VGIII 5'-p-GCT TGG GTG TTC TCA TTC ATC GAT CAT gct tct tgg gtc ccc atT CTA GTA CAG AGC TTC TCC Gcc gcg acg aca tag TCT AGT CAA CAA TGA CAG GTC TGC TTA-3' |
| VGIV 5'-p-GCT TGG GTG TTC TCA TTC ATC GAT CAT gct tct tgg gtc ccc atT CTA GTA CAG AGC TTC TCC Gcc gcg acg aca tag TCT AGT CAA CAA TGA CAG GTC TGC TTA-3' |
| RCA1 5'-ATG GGC ACC GAA GAA GCA-3' |
| RCA2 5'-CGC GCA GAC AGC ATA-3' |
| Semi-nested F 5' – TGG ATT AGA ATT GCC ACT GTA AG - 3' |

Note: The 5'- and 3'-ends of the probes that are complementary to the target sequences are underlined. The regions where the two padlock probe-specific primers (RAC1 and RCA2) bind for real-time amplification are in lower case letters. The 5'-end of probe, p-indicates phosphorylation. Ambiguous positions were introduced according to the target sequences (in bold): M = A or C, K = G or T, R = A or G, S = C or G.

doi:10.1371/journal.pone.0094648.t002

Identification of Cryptococcus spp. by HRCA

Probe signals were amplified by incubation at 65°C for 30 min and the accumulation of dsDNA products was monitored in a Corbett RotorGene 3000 real-time PCR machine. Alternatively the end products could also be loaded on a 1.5% agarose gel and visualized under UV light. The positive signals are then visualized as a ladder of bands, starting at one unit circle length and extending in discrete increments to several thousands of nucleotides.

Results

Locus Selection

From the 7 analyzed MLST loci, the PLB1 locus was the only one to contain specific SNPs for all 7 major haploid molecular types (Table 1), including the two most genetically related, VNI and VNII molecular types (Figure 1A). Furthermore, the PLB1 locus has the advantage of being amplified from all molecular types using only a single primer pair. Unlike for the loci SOD1, GPDI and LAC1, for which different primer pairs are needed to amplify these loci from either C. neoformans or C. gattii, which would require a previous identification of both species. In addition, the IGS1 fragments are highly polymorphic and do not present specific SNPs for each major haploid molecular type. Finally the SOD1 locus exhibited very low polymorphism among the C. neoformans strains, which does not allow for a differentiation amongst its major molecular types.

Primer Specificity

To demonstrate the specificity of the used primers, the PLB1 locus [13] was also attempted to be amplified from different fungal species, including: Candida albicans, C. dubliniensis, C. krusei, C. glo-boa, Scedosporium prolificans, Aspergillus fumigatus, and Fusarium solani, commonly found in clinical specimens. No amplification was obtained from any of those species using the PLB1 specific primers of the ISHAM C. neoformans/ C. gatti consensus MLST scheme (data not shown). In addition BLAST searches using the primer sequences reveal only a homology to either C. neoformans or C. gatti and did not find any matches to other basidiomycetous yeasts such as C. laurentii, C. albicans, C. uniguttulatus or Trichosporon spp.

HRCA

HRCA amplification in combination with the detection of the generated products on a real-time-PCR was applied to ten representative strains of each major haploid molecular type (Figure 1B), as well as to 4 C. neoformans VNIII hybrids (Figure 1D) and 2 inter-species C. neoformans/ C. gatti hybrids (Figure 1C). A signal generated with the respective probes demonstrated a positive result, while no signal indicated negative results. The results of the real-time-PCR are listed in Table 1. All C. neoformans VNI, VNII and VNIV strains, C. gatti VGI, VGII, VGIII and VGIV, and the hybrid strains (VNIII and VNI/VGII) studied generated positive signals with the respective HRCA probes (Figure 1B, 1C and 1D). The probes targeting VGIII also annealed to six additional strains, which were previously identified as VGIV by URA5-RFLP. However, those strains showed a much closer relationship to the VGIII strains than to the VGIV in the ISHAM MLST scheme, see the phylogenetic tree in Figure 1A, represented by WM 1802, WM 2004, WM 2042 and WM 11.32. The URA5 gene sequence analysis of those strains demonstrated one point mutation, affecting the restriction site of the enzyme Sau96I at the position 528 in this group of strains (WM 1802, WM 1804, WM 2004, WM 2041, WM 2042, WM 11.135), which resulted in the same fragments as the ones obtained for the major molecular type VGIV.

Sensitivity of the Detection Method

In order to obtain the required sensitivity for a direct diagnosis of cryptococcosis from clinical or other DNA low-abundance samples, a semi-nested PCR was developed, which then was used in combination with HRCA on DNA dilutions of selected cryptococcal samples as proof of principle. When the semi-nested-F primer sequence for the PLB1 locus was compared...
against the GenBank database it showed BLASTN hits with greater than 98% identity to the *C. neoformans* and *C. gattii* *PLB1* gene only. This demonstrated that it has a high specificity for *C. neoformans* and *C. gattii*. As such this primer was used in combination with the *PLB1*-R primer [13] using the PCR products from the initial *PLB1* amplification as a template to amplify a fragment of 607 bp (Table 2). The methodology then was applied on serial dilutions of DNA from *C. neoformans* and *C. gattii* cultures to determine if the sensitivity would be adequate for a possible detection directly from clinical specimens, resulting in 10 ng of DNA as the lowest limit for HRCA detection. When the semi-nested PCR strategy was applied, the sensitivity of the single copy gene detection was enhanced, enabling the detection of a minimum of 40 copies of DNA (approximately 1 pg of DNA), which is essential for the direct detection of the molecular types or species from clinical specimens (Figure 2).

Figure 1. Association between MLST clusters and HRCA curves. (A) Unrooted neighbor-joining tree inferred from the combined sequences of *CAP59*, *GPD1*, *LAC1*, *SOD1*, *URA5*, *PLB1* genes and IGS of 76 strains tested in this study. Numbers on branches are bootstrap support values obtained from 1,000 pseudoreplicates. *VGII* only when determined by the ISHAM MLST scheme, *URA5* RFLP is grouping them incorrectly to VGIV due to a point mutation in the RFLP restriction site; (B) Amplification curves for representative strains of each major haploid molecular type, *C. neoformans* molecular types VNI, VNII and VNIV and *C. gattii* molecular types VGI, VGII, VGIII and VGIV obtained with the respective HRCA probes. (C) *C. neoformans*/*C. gattii* VNI+VGII hybrid strain (WM 05.532), positive amplification with the HRCA probes VNI-PLB and VGII-PLB. (D) *C. neoformans* VNIII hybrid strain (WM 628), positive amplification with the HRCA probes VNI-PLB and VNIV-PLB. Positive results are indicated when the fluorescence signals increased exponentially.

doi:10.1371/journal.pone.0094648.g001
a 1.4% agarose gel.

Furthermore, cytokines, chemokines, and their receptors are associated with manifestations [29]. Regarding fungal infections this association is associated to different genotypes of the virus, as well as to genetic differences [28]. Similar findings have been made in connection with the lower detection limits range from 10 fg [34] to 500 pg [35]. However, the ribosomal regions are unable to differentiate all major molecular types within C. neoformans [36].

For the first time HRCA of the PLB1 locus alone or together with the application of the herein developed semi-nested PCR approach showed to be a specific and highly sensitive methodology, with a great potential to be used on DNA extracts from pure cultures or clinical specimens for the direct identification of the different major molecular types within C. neoformans [36].

To enable a direct detection form clinical specimens the sensitivity was increased via the development of a semi-nested PCR. This increased the detection limit to approximately 1 pg of DNA equaling a minimum of 40 copies of DNA. This brings the detection limit in the range of the DNA amounts being detected by multicolor regions, such as the ribosomal gene cluster, which is widely used as a target for the detection of fungal disease agents, where the lower detection limits range from 10 fg [34] to 500 pg [35]. However, the ribosomal regions are unable to differentiate all major molecular types within C. neoformans [36].

Specific padlock probes in combination with hyperbranched rolling circle amplification (HRCA) are ideal for the development of diagnostic assays, which require speed, specificity and reproducibility. The application of loop-mediated isothermal DNA amplification (LAMP) using the capsule-associated gene CAP59 [23] was only able to identify the serotypes A and D of C. neoformans and C. gattii, but was not able to differentiate the serotypes B and C of C. gattii. Kaocharoen et al. [22] applied also HRCA to detect the major molecular types of C. neoformans and C. gattii using the internal transcribed spacer (ITS) regions of the rDNA gene cluster as a target. However, this enabled only the differentiation between VNI/VNII, VNIV and C. gattii. Feng et al. developed a duplex PCR assay using vacuolar membrane gene to differentiate between the molecular types of C. gattii [33], but this did not simultaneously enable the differentiation of the major molecular types of C. neoformans. The current study detected specific SNPs for each of the major haploid molecular types of C. neoformans (VNI-VNIV) and C. gattii (VGI-VGIV) in the PLB1 locus, allowing for the development of specific padlock probes. HRCA using the PLB1 locus was able to differentiate the seven major haploid molecular types of C. neoformans (VNI, VNII, VNIV) and C. gattii (VGI, VGII, VGIII, VGIV) and also identified correctly different types of hybrid isolates from DNA extracts from pure cultures.

**Discussion**

Improved technologies, which accurately identify the different molecular types of C. neoformans and C. gattii or the separation of specific genotypes within those molecular types, have been increasingly important for prognostic and therapeutic implications. Despite the similar clinical features between the two species, infections caused by C. gattii have the tendency to induce massive inflammation and cryptococcomatas, and require additional clinical follow up. The major molecular types of C. neoformans (VNI-VNIV) and C. gattii (VGI-VGIV) are not identified in routine laboratories and the virulence of the different genotypes has not been systematically studied, although those molecular types have molecular, epidemiological, serological and antifungal susceptibility differences [28]. Similar findings have been made in connection with the clinical outcomes of viral infections, which have been associated to different genotypes of the virus, as well as to genetic variations of immune genes, leading to more severe clinical manifestations [29]. Regarding fungal infections this association is unclear, but genetic variations in immune genes encoding cytokines, chemokines, and their receptors are associated with the risk for invasive mold diseases [30] and are also associated with persistent fungemia in candidemia patients [31]. Furthermore, certain MLST genotypes of C. neoformans were associated with a higher mortality among HIV patients in sub-Saharan Africa [32], and isolates of such genotypic group exhibited increased capsule and a more pronounced Th2 response. The same study also showed that C. neoformans hybrids strains were associated with increased mortality in humans, although they had attenuated virulence in mouse models [31]. All those facts together emphasize the urgent need for a differential diagnosis of the different molecular type causing human infections.

Specific padlock probes in combination with hyperbranched rolling circle amplification (HRCA) are ideal for the development of diagnostic assays, which require speed, specificity and reproducibility. The application of loop-mediated isothermal DNA amplification (LAMP) using the capsule-associated gene CAP59 [23] was only able to identify the serotypes A and D of C. neoformans and C. gattii, but was not able to differentiate the serotypes B and C of C. gattii. Kaocharoen et al. [22] applied also HRCA to detect the major molecular types of C. neoformans and C. gattii using the internal transcribed spacer (ITS) regions of the rDNA gene cluster as a target. However, this enabled only the differentiation between VNI/VNII, VNIV and C. gattii. Feng et al. developed a duplex PCR assay using vacuolar membrane gene to differentiate between the molecular types of C. gattii [33], but this did not simultaneously enable the differentiation of the major molecular types of C. neoformans. The current study detected specific SNPs for each of the major haploid molecular types of C. neoformans (VNI-VNIV) and C. gattii (VGI-VGIV) in the PLB1 locus, allowing for the development of specific padlock probes. HRCA using the PLB1 locus was able to differentiate the seven major haploid molecular types of C. neoformans (VNI, VNII, VNIV) and C. gattii (VGI, VGII, VGIII, VGIV) and also identified correctly different types of hybrid isolates from DNA extracts from pure cultures.

**Supporting Information**

**Table S1** Accession number of the sequences included in the study to design the semi-nested PCR primer.

(XLS)
Acknowledgments

The authors would like to thank all our collaborators from around the world for supplying the strains used in this study to evaluate the herein developed HRCA method.

Author Contributions

Conceived and designed the experiments: WM LT B. Wanke ML B. Wang. Performed the experiments: LT B. Wang CF. Analyzed the data: LT WM. Contributed reagents/materials/analysis tools: WM B. Wang. Wrote the paper: LT WM B. Wanke ML B. Wang CF.

References

1. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, et al. (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 50(3): 291–222.

2. Harris J, Lockhart S, Chiller T (2012) Cryptococcus gattii where do we go from here? Med Mycol 50(2): 113–129.

3. Lázera MS, Gutiérrez-Galardo MC, Cavalanti MAS, Wanke B (2005) Cryptococcus gattii. In: Coura JR, editor. Dinâmica das doenças infecciosas e parasitárias, Guanabara Koogan, Rio de Janeiro. 1223–1236.

4. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, et al. (2004) A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 101(49): 17258–17263.

5. Meyer M, Gilgado F, Ngamskulrungroj P, Trilles L, Hagen F, et al. (2011) Molecular Typing of the Cryptococcus neoformans/C. gattii species complex, p 327–337. In: Heitman J, Kozel T, Kwon-Chung J, Perfect J, Casadevall, editors. Cryptococcus: from human pathogen to model yeast. ASM Press, Washington, DC.

6. Trilles L, Meyer W, Wanke B, Guarro J, Lázera MS (2012) Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med Mycol 50(3): 328–332.

7. Sorrell TC (2001) Cryptococcus neoformans. In: Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, et al. (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 50(3): 291–222.

8. Byrnes EJ 3rd, Li W, Ren P, Lewit Y, Voelz K, et al. (2011) A diverse population of Cryptococcus gattii molecular type VGII in Southern Californian HIV/AIDS patients. PLoS Pathog 7(9): e1002203.

9. Boekhout T, Theelen B, Diaz M, Fell JW, Hop WC, et al. (2001) Hybrid genotypes in the pathogenic yeast species Cryptococcus. Microbiology 147(4): 891–907.

10. Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E, et al. (2003) Molecular typing of the Dornemann Cryptococcus neoformans isolates. Emerg Infect Dis 9(2): 189–192.

11. Hanafy A, Kaocharoen S, Jover-Botella A, Katsu M, Iida S, et al. (2008) Microsatellite multilocus typing for Cryptococcus neoformans var. grubii. Med Mycol 46(7): 625–636.

12. Meyer W, Anzenen DM, Boekhout T, Cogliati M, Diaz MR, et al. (2009) Consensus multilocus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 47(6): 561–570.

13. Mager PT, Gale C, Berman J, Davis D (2003) Molecular genetic and genomic approaches to the study of medically important fungi. Infect Immun 71(5): 2577-2584.

14. Magee PT, Gale C, Berman J, Davis D (2003) Molecular genetic and genomic approaches to the study of medically important fungi. Infect Immun 71(5): 2577-2584.

15. Leav SN, Chang HC, Sun HF, Barton R, Bouchara JP, et al. (2006) Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J Clin Microbiol 44(3): 693–699.

16. Bowers M, Diaz MR, Hagen F, Spanjaard L, Duin B, et al. (2007) Identification of genetically diverse Cryptococcus neoformans and Cryptococcus gattii isolates by Luminex xMAP technology. J Clin Microbiol 45(5): 1874–1883.

17. Lazari PM, Huang XH, Zhu ZG, Bray-Ward P, Thomas DC, et al. (1998) Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nat Genet 19: 225–232.

18. Nilson M, Malmgren H, Samiotaik M, Kwiatkowski M, Chudhary BP, et al. (1994) Padlock probes: circularizing oligonucleotides for localized DNA detection. Science 265: 2085–2088.

19. Alsmadi OA, Bornarth CJ, Song W, Winiweski M, Du J, et al. (2003) High accuracy genotyping directly from genomic DNA using a rolling circle amplification based assay. BMC Genomics 4(1): 21.